Selecta Biosciences, Inc. (SELB)

NASDAQ: SELB · IEX Real-Time Price · USD
1.78
+0.06 (3.49%)
At close: Jan 27, 2023, 4:00 PM
1.77
-0.01 (-0.56%)
After-hours: Jan 27, 2023, 7:40 PM EST
3.49%
Market Cap 272.40M
Revenue (ttm) 123.92M
Net Income (ttm) 41.73M
Shares Out 153.03M
EPS (ttm) 0.21
PE Ratio 8.48
Forward PE 25.45
Dividend n/a
Ex-Dividend Date n/a
Volume 670,790
Open 1.71
Previous Close 1.72
Day's Range 1.69 - 1.80
52-Week Range 0.65 - 2.73
Beta 0.98
Analysts Buy
Price Target 6.99 (+292.7%)
Earnings Date Mar 9, 2023

About SELB

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, includin... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Carsten Brunn
Employees 58
Stock Exchange NASDAQ
Ticker Symbol SELB
Full Company Profile

Financial Performance

In 2021, SELB's revenue was $85.08 million, an increase of 412.60% compared to the previous year's $16.60 million. Losses were -$25.69 million, -62.71% less than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for SELB stock is "Buy." The 12-month stock price forecast is $6.99, which is an increase of 292.70% from the latest price.

Price Target
$6.99
(292.70% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Selecta Biosciences Provides Business Update and Outlook for 2023

- Expected topline data for Phase 3 DISSOLVE I & II programs of SEL-212 in chronic refractory gout in Q1 2023 -

2 weeks ago - GlobeNewsWire

Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease

Next-generation IgG protease candidate Xork to be licensed for development with AT845, an investigational Astellas Gene Therapies' product, for the treatment of Pompe Disease Selecta to receive a $10M...

2 weeks ago - PRNewsWire

Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program

– IgA protease candidate in combination with ImmTOR further enhances pipeline –

1 month ago - GlobeNewsWire

Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer

WATERTOWN, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therap...

2 months ago - GlobeNewsWire

Selecta Biosciences to Participate at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day

WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platfo...

2 months ago - GlobeNewsWire

Selecta Biosciences, Inc. (SELB) Reports Q3 Loss, Lags Revenue Estimates

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -200% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the ...

3 months ago - Zacks Investment Research

Selecta Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

– DISSOLVE I & II studies of SEL-212 in Chronic Refractory Gout remain on track for joint topline data readout in Q1 2023 –

3 months ago - GlobeNewsWire

Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Business Update

WATERTOWN, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platfo...

3 months ago - GlobeNewsWire

Selecta Biosciences Announces Three Presentations at the Upcoming 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference

Data to be featured in one poster and two oral presentations Data to be featured in one poster and two oral presentations

3 months ago - GlobeNewsWire

Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions

WATERTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platf...

4 months ago - GlobeNewsWire

Selecta Biosciences to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic thera...

4 months ago - GlobeNewsWire

Selecta Biosciences to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic thera...

5 months ago - GlobeNewsWire

Selecta Biosciences, Inc. (SELB) Q2 Earnings and Revenues Surpass Estimates

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 300% and 83.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

– Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish Orphan Biovitrum AB (publ.) (Sobi); DISSOLVE I & II studies remain on track for joint topline ...

6 months ago - GlobeNewsWire

Selecta Biosciences, Inc. (SELB) Upgraded to Strong Buy: Here's What You Should Know

Selecta Biosciences, Inc. (SELB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near te...

6 months ago - Zacks Investment Research

Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Business Update

WATERTOWN, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therap...

6 months ago - GlobeNewsWire

Selecta Biosciences to Participate at the Guggenheim I&I Spotlight Series – Treg-based Therapies Conference

WATERTOWN, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therap...

7 months ago - GlobeNewsWire

Selecta Biosciences Announces Partnership Advancements and Clinical Trial Updates

-Sarepta extends Research License and Option Agreement for ImmTOR® in Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophies-

8 months ago - GlobeNewsWire

SVB Leerink Sees Over 600% Upside For This Penny Biotech Stock

SVB Leerink initiated Selecta Biosciences Inc (NASDAQ: SELB) coverage with an Outperform rating and a price target of $7. The analysts view ImmTOR's approach to mitigate ADAs as de-risked by early cli...

8 months ago - Benzinga

Selecta Biosciences to Participate at the H.C. Wainwright Global Investment Conference

WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapi...

9 months ago - GlobeNewsWire

Selecta Biosciences, Inc. (SELB) Reports Q1 Loss, Tops Revenue Estimates

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 22.22% and 80.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the sto...

9 months ago - Zacks Investment Research

Selecta Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update

– Phase 1 trial of SEL-302 remains on track to initiate in the second half of 2022 –

9 months ago - GlobeNewsWire

Selecta Biosciences Announces Six Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Data to be featured in two oral presentations and four poster presentations Data to be featured in two oral presentations and four poster presentations

9 months ago - GlobeNewsWire

Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update

WATERTOWN, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic thera...

9 months ago - GlobeNewsWire

Selecta Biosciences Announces $38.7 Million Underwritten Offering

WATERTOWN, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta” or the “Company”), a biotechnology company focused on developing tolerogenic therapies to mitig...

10 months ago - GlobeNewsWire